Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Am J Clin Pathol ; 108(6): 641-51, 1997 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-9384445

RESUMO

Small intestinal stromal tumors (SISTs), similar to their gastric counterpart, are complex because of their divergent cellular differentiation and because of the difficulty in accurately predicting their clinical outcome. We studied a series of 22 SISTs from 20 patients to characterize lineage and investigate prognostic morphologic parameters and possible histologic and immunohistochemical differences from gastric stromal tumors (GSTs) and to determine the potential prognostic value of proliferation markers. Cases were categorized into the three following groups based on mitotic count (MC) per 50 high-power fields and tumor size: (1) benign, n = 6 (< 5 MC, < 5 cm); (2) borderline, n = 6 (< 5 MC, > or = 5 cm); and (3) malignant, n = 10 (> or = 5 MC, any size). For the formalin-fixed, paraffin-embedded tissue sections, an immunohistochemical panel was used to characterize differentiation toward myogenic cells (pan-muscle specific actin [HHF-35], alpha-smooth muscle actin, and desmin), Schwann cells (S-100 protein), enteric glial (glial fibrillary acidic protein), and nerve cells (neurofilament). Cellular proliferative activity was assessed immunohistochemically using monoclonal antibodies to proliferating cell nuclear antigen (PCNA) and Ki-67 antigen (MIB-1) and a tumor proliferation index (TPI) was obtained as the percentage of positive-staining tumor nuclei. Clinical follow-up revealed that none of the benign tumors progressed (mean follow-up, 96 months). Half of the patients with borderline tumors were dead of disease (mean, 50.7 months), while 8 of 9 patients with a malignant tumor died of disease (mean, 24.6 months). By Cox Proportional Hazard Regression analysis, mitotic count, tumor size, and cellularity significantly predicted survival. PCNA, MIB-1, tumor necrosis, and atypia were not significant predictors of survival. All tumors stained with vimentin; 17 (77%) and 13 (59%) of the tumors showed immunoreactivity with muscle-specific actin markers (HHF-35) and alpha-smooth muscle actin, respectively. Only 1 tumor stained with desmin, and none stained with S-100 protein, neurofilament, or glial fibrillary acidic protein. Immunophenotypic characteristics did not differ among the 3 groups. The TPI for PCNA and MIB-1 significantly differed between benign and malignant tumors and between borderline and malignant tumors, but it failed to separate the benign and borderline groups. Compared with 52 cases of GST previously reported by us using the same criteria and antibody panel, these tumors were histologically and immunohistochemically indistinguishable. However, none of the 18 borderline GSTs progressed, while 3 of 6 patients with a borderline SIST died of the disease. Based on this series of 22 SISTs, we conclude the following: (1) MC, size, and cellularity are the best predictors of clinical outcome in SIST. (2) The majority of SISTs show smooth muscle differentiation based on their immunoreactivity with HHF-35 and alpha-smooth muscle actin). (3) The TPI for PCNA and MIB-1 correlated with MC but failed to predict survival for individual cases. (4) SISTs and GSTs are morphologically and immunohistochemically similar; however, SISTs seem to have greater malignant potential than GSTs of similar size.


Assuntos
Neoplasias Intestinais/química , Neoplasias Intestinais/patologia , Antígeno Nuclear de Célula em Proliferação/análise , Células Estromais/patologia , Actinas/análise , Adulto , Idoso , Idoso de 80 Anos ou mais , Biomarcadores/análise , Diferenciação Celular , Neoplasias Duodenais/química , Neoplasias Duodenais/mortalidade , Neoplasias Duodenais/patologia , Feminino , Humanos , Neoplasias do Íleo/química , Neoplasias do Íleo/mortalidade , Neoplasias do Íleo/patologia , Imuno-Histoquímica , Neoplasias Intestinais/mortalidade , Neoplasias do Jejuno/química , Neoplasias do Jejuno/mortalidade , Neoplasias do Jejuno/patologia , Antígeno Ki-67/análise , Masculino , Pessoa de Meia-Idade , Índice Mitótico , Valor Preditivo dos Testes , Prognóstico , Neoplasias Gástricas/química , Neoplasias Gástricas/patologia , Taxa de Sobrevida
2.
Int J Gynecol Pathol ; 13(3): 273-8, 1994 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-7928060

RESUMO

Benign retroperitoneal cysts (RPCs) of müllerian type may present as a pelvic mass in a perimenopausal or postmenopausal woman, and thus clinically can mimic an ovarian malignancy. We report three women, aged 73, 45, and 68 years, who presented with large RPC masses ranging from 8 to 17 cm in diameter. Histologically, the cysts were lined by benign müllerian-type epithelium: serous epithelium in two patients and mucinous epithelium in one patient. A malignant component was not present in any of the cases. Preoperative diagnosis in two patients was ovarian carcinoma based on clinical and computerized tomography findings. Two patients are alive without evidence of disease 44 and 56 months following surgical excision, whereas one patient died of perioperative complications unrelated to the cystic lesion. Similar previously reported cases and their possible pathogenetic mechanisms are discussed. Although the müllerian type of RPCs behave in a benign manner, a malignant component has to be searched for. Thus, complete excision with careful histologic examination rather than drainage or marsupialization is recommended.


Assuntos
Cistos/patologia , Ductos Paramesonéfricos/patologia , Espaço Retroperitoneal/patologia , Idoso , Feminino , Humanos , Pessoa de Meia-Idade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...